Sartorius Aktiengesellschaft (SRT.DE)
| Previous close | 410.00 |
| Open | 410.50 |
| Bid | 407.00 x 18800 |
| Ask | 408.50 x 13500 |
| Day's range | 406.50 - 416.50 |
| 52-week range | 276.50 - 834.00 |
| Volume | |
| Avg. volume | 2,333 |
| Market cap | 29.218B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 57.00 |
| EPS (TTM) | 7.14 |
| Earnings date | 19 Oct 2022 |
| Forward dividend & yield | 1.25 (0.30%) |
| Ex-dividend date | 28 Mar 2022 |
| 1y target est | 497.50 |
- Reuters
Sartorius sticks to 2022 outlook despite rising costs, Ukraine
FRANKFURT (Reuters) -Franco-German lab supplies group Sartorius AG stuck to its 2022 outlook on Thursday as demand remained strong in the first quarter despite uncertainties from the war in Ukraine. Sartorius, which competes in bioreactor gear with Merck KGaA and Thermo Fisher, said underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) had increased by nearly a third from the same quarter last year to reach 349 million euros ($378.28 million). The corresponding underlying EBITDA margin improved to 34.1%, said the company which last year entered Germany's blue-chip index DAX.
- EQS Group
Pareto Securities advises Karin Sartorius-Herbst in connection with the increase of her shares in the community of heirs of Horst Walter Sartorius
DGAP-News: Pareto Securities AS / Key word(s): Statement10.03.2022 / 09:00 The issuer is solely responsible for the content of this announcement.Pareto Securities advises Karin Sartorius-Herbst in connection with the increase of her shares in the community of heirs of Horst Walter SartoriusFrankfurt, March 10, 2022. The investment bank Pareto Securities advised Karin Sartorius-Herbst through its Frankfurt office in connection with the increase of her shares in the community of heirs of Horst Wal
- Reuters
Exclusive-Sartorius in $11 billion bid for COVID vaccine reagent vendor Maravai -sources
(Reuters) -Laboratory supplies vendor Sartorius AG has approached Maravai LifeSciences Holdings Inc, a U.S. provider of capping reagents for COVID-19 vaccines, with an $11 billion acquisition offer, people familiar with the matter said. Maravai rejected the $42 per share all-cash offer from Goettingen, Germany-based Sartorius earlier this month as inadequate, the sources said. It is not clear whether Sartorius will return with a new offer or whether Maravai will attract acquisition interest from other laboratory equipment and supplies providers.
